Ultragenyx Pharmaceutical Inc. (RARE), a public biopharmaceutical company, has been making waves in the pharmaceutical industry with its commitment to developing innovative treatments for patients with rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, Ultragenyx has been built on a foundation of determination and scientific brilliance.
The company's mission is clear: "Transform the treatment of rare and ultra-rare diseases by driving innovation and delivering value to patients" and over the past decade, Ultragenyx has made significant strides towards making this a reality. So far, the company has obtained approval for and launched three novel therapies, namely Crysvita (for X-linked hypophosphatemia and Tumor-Induced Osteomalacia), Mepsevii (for Mucopolysaccharidosis VII), and Dojolvi (for Long-Chain Fatty Acid Oxidation Disorders). These approvals mark important milestones for Ultragenyx, and more importantly, bring much needed hope and treatment options for patients living with these diseases.
In addition to these, Ultragenyx has built an extensive pipeline of promising drug candidates to address other devastating genetic diseases. It is known for applying its knowledge and unique infrastructure to manage the complexities of developing and delivering therapies to patients with rare genetic diseases. Ultragenyx is committed to patient centricity and maintains direct dialogues with patients and caregivers to understand their journey and challenges.
Ultragenyx's dedication to scientific innovation and patient welfare is reflected in its strategic collaboration with production partners and medical communities around the world. The company takes pride in its specialized teams, who strive to develop breakthrough therapies by pushing the boundaries of creativity and possibility.
Another notable achievement of Ultragenyx is its conscious effort to foster a culture of transparency, teamwork, courage, and relentless passion for creating the extraordinary. The company ardently promotes these values and has created a culture where employees can bring their best selves to work.
What elevates Ultragenyx in the pharmaceutical industry is not just the company's dedication to cultivating novel treatments for rare diseases, but also its commitment to operating sustainably and responsibly. With a keen eye for the future, this company is playing a significant role in transforming the face of the rare disease landscape, thereby bringing hope and improved quality of life to countless patients and families globally.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Ultragenyx Pharmaceutical is reducing its workforce by approximately 20% (about 250 positions) and terminating its drug programs for Angelman syndrome and Wilson disease. These cuts, which are expected to save the company money in research and administrative costs, come months after the FDA approved two of its gene therapies for glycogen storage disease type Ia and Sanfilippo syndrome type A. The company aims for full-year profitability by 2027 and continues to advance other clinical programs.
Privium Fund Management B.V. significantly reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 31.2% in the third quarter of 2026, selling 105,763 shares. This reduction comes as Ultragenyx reported a quarterly loss that missed estimates and revenue below consensus, despite year-over-year growth. Analyst opinions are mixed, with a "Hold" consensus rating and an average target price of $29.79, while the company's investigational Sanfilippo syndrome gene therapy is under UK regulatory review.
Ultragenyx Pharmaceutical has submitted a marketing application to the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its gene therapy, UX111, designed to treat Sanfilippo syndrome. This submission marks a significant step towards potentially making the therapy available for patients in the UK. Sanfilippo syndrome is a rare, genetic metabolic disorder that primarily affects the brain and spinal cord.
Ultragenyx Pharmaceutical (NASDAQ:RARE) has received acceptance from the UK's MHRA for its UX111 gene therapy marketing authorization application for Sanfilippo syndrome Type A. The company is coordinating its NICE assessment with the regulatory review and aims for a funding appraisal decision to follow marketing authorization. The European Medicines Agency has also begun its review of the application.